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Abstract 
 
The development of new 2D and 3D phenotypic screening assays combined with high-
throughput genomic and proteomic technologies are well placed to advance a new era of 
molecular pathway informed Phenotypic Drug Discovery. We describe the application of 
Reverse Phase Protein Array (RPPA) technology to elucidate the mechanism-of-action of 
small molecules at the post-translational pathway level. We propose that profiling of 
phenotypic hits and lead molecules in increasingly more complex 3D in vitro and ex vivo 
models at the post-translational pathway network level represents an effective strategy to 
both triage and progress the preclinical development of phenotypic screening hits. 
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Introduction 
 
Advances in new cell based assay technologies including primary patient-derived cell culture 
protocols, induced pluripotent stem cell technology, precise genome editing, 3-dimensional 
and microfluidic cell culture systems and automated high content imaging and image-
informatics are converging to stimulate an exciting new era of phenotypic drug discovery [1, 
2]. Such breakthroughs in cell culture technologies provide new opportunities to custom 
design phenotypic screening assays, which more accurately represent the genetic drivers 
and pathophysiology of diseased tissue [3]. The development of new cell based assay 
technologies promise to advance drug discovery into new disease areas, which have not 
previously been tractable to in vitro model systems [4]. While cell based assay technologies 
provide important functional assays to support target validation and subsequent testing of 
hit and lead molecules from target directed drug discovery strategies, their integration with 
automated liquid handling robotics and automated phenotypic data analysis pipelines 
provides new opportunities to incorporate more complex cell assays into phenotypic 
screening projects in the absence of molecular target hypotheses. In this article we highlight 
some of the challenges in de-convoluting the mechanism-of-action of small molecules 
identified as phenotypic hits at an individual molecular target level. We discuss how a high 
throughput antibody-based proteomics method called Reverse Phase Protein Array (RPPA) 
can help to profile compound mechanism-of-action at the post-translational pathway 
network level across dose-response and time-series studies performed in both 2D and 3D 
cell models to progress further preclinical development of phenotypic hits in an efficient 
manner.  
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Target deconvolution and mechanism-of-action profiling strategies in phenotypic drug 
discovery.  
Phenotypic screening as defined in this article as “target agnostic screening and selection of 
hit molecules, lead compounds and approved drugs based on quantifiable phenotypic 
endpoints” has been proposed as an empirical drug discovery approach to identify new 
therapeutic targets or alternatively to accelerate target-agnostic drug discovery and 
development strategies [1, 2, 5]. In support of phenotypic-led discovery of new targets, cell 
based assay screening technologies are further complemented by advances in target 
deconvolution technologies, including chemical proteomics methods such as affinity mass 
spectrometry and thermostability shift assays, cDNA expression microarray technologies, 
haploid genetic/gene trap and whole genome CRISPR screening performed in parallel with 
pharmacological phenotypic assays among others [6-12]. 
However, the target deconvolution paradigm and associated methods described above 
make a number of assumptions, which are unlikely to be suitable for all phenotypic hits and 
disease models or the human disease indications which they represent. For example, the 
majority of target deconvolution strategies assume that the phenotypic hit or lead molecule 
exerts its phenotypic response through modulation of a single protein target, which does 
not account for compounds modifying phenotypes through multi-targeted 
polypharmacology or adaptation and reprogramming of transcriptional and post-
translational pathway networks. For many complex disease and gain-of-function phenotypic 
assays it may also be unlikely that the one-drug/one-target paradigm will be sufficient to 
restore normal cell or tissue physiology and thus more complex multi-targeted approaches 
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will be required to reprogram cellular phenotypes. Furthermore, chemical proteomic 
strategies identify multiple proteins which bind to compounds, which necessitate 
substantial follow up with functional genomic studies to identify which protein binders 
represent the key therapeutic target responsible for the pharmacologically induced 
phenotype. Critical to the identification of true compound targets regulating cell phenotype 
over false positive non-specific binding interactions is the need to incorporate several 
negative control samples into the chemical proteomic workflow. Such negative control 
samples may include, inactive isomers of hit compounds, comparison of protein interaction 
profiles in extract from cells which show no or distinct phenotypic response to compound 
hits and negative (background control) samples using linker-bound affinity matrix (no 
compound) only samples. It is also unlikely that initial hits from a phenotypic screen will 
have sufficient potency or selectivity to support effective target deconvolution studies and 
thus further medicinal chemistry to improve potency and understand structure activity 
relationships with regards to phenotypic response will be required prior to instigating a 
target deconvolution program. Thus, there is a significant risk that poorly designed 
phenotypic screening and target deconvolution strategies may create expensive new drug 
discovery bottlenecks in target deconvolution and further investment of significant 
chemistry resources on poorly validated targets, which, do not directly address specific 
disease conditions and urgent unmet clinical needs. 
We propose that target deconvolution should not be instigated early in a phenotypic drug 
discovery program. Rather, phenotypic leads should be carefully triaged through 
increasingly more complex and disease relevant secondary phenotypic assays to build 
further confidence in their translational potential and a deeper understanding of 
mechanism-of-action at transcriptome and post-translational pathway levels to support 
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both, subsequent target deconvolution activities or further preclinical development with or 
without knowledge of the target (Figure 1). This more broader view of profiling the 
mechanism-of-action of phenotypic hits beyond a single molecular target is facilitated by 
the development of new rapid and high-throughput genomic, proteomic and phenotypic 
profiling methodologies [13-15]. Recent advances in mechanism-of-action profiling 
technologies include high throughput gene transcription profiling [13, 16]. For example, the 
Connectivity Map program developed by the Broad Institute combines a public repository of 
gene expression profiles collected from large panels of compound perturbed samples with 
computational and statistical methods to support similarity profiling of gene expression 
patterns to infer compound MOA [13]. Further technical advances in higher throughput and 
more cost-effective gene-expression methods such as the L1000™ expression profiling 
platform which underpins the Library of Integrated Cellular Signatures (LINCS) NIH program, 
supports drug MOA profiling at the transcriptional level at scale [16-18]. The impact of 
higher throughput transcriptional profiling upon phenotypic drug discovery programs 
remains to be fully determined and will likely depend upon optimal experimental designs 
and inclusion within logical phenotypic drug discovery workflows to ensure these methods 
are applied to the most appropriate compounds and cell models. While many of the 
underlying causes of cancer occur at genetic and epigenetic levels, the direct targets of 
drugs are typically functional proteins, and thus drug MOA and the most appropriate 
pharmacodynamic biomarkers are likely to be discovered at the protein level. Also for those 
complex disease traits that do not represent single gene disorders, understanding the 
dynamic post-translational pathway networks that control and predict therapeutic response 
across a heterogeneous patient population and evolving disease progression are essential to 
progress effective drug discovery and development. Therefore, only by studying the 
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dynamic state of the proteome and its functional states we can obtain a clear understanding 
of the relationship between a drug's mechanism and disease to adequately inform 
biomarker discovery and drug development programs that embrace the complexities of 
disease. 
Traditionally, functional proteomic methodology has relied on quantitative mass-
spectrometry techniques such as ITRAQ (Isobaric Tags for Relative and Absolute 
Quantitation) and SILAC (Stable Isotope Labelling with Amino acids in Cell culture), which 
remain the standard approaches for de novo identification of post-translational biomarkers 
[19]. However, limitations in speed, cost, sensitivity and reproducibility of quantitative mass 
spectrometry approaches has restricted their routine application across multiple samples at 
scale. The evolution of antibody-based RPPA, combined with more sophisticated sample 
handling, optical detection and better quality (validated mono-specific) antibody reagents, 
provide an alternative approach enabling exquisite sensitivity and substantial sample 
throughput of functional proteomic analysis across multiple pathways [20, 21]. Analysis of 
protein abundance and post-translational activation states of pathways across dose-
response and time series may be a more appropriate and informative methodology toward 
identification of pharmacodynamic or predictive biomarkers to progress phenotypic hits.  
 
Reverse Phase Protein Array (RPPA) platforms 
RPPA represents a high-throughput and miniaturized immunoassay methodology, which 
provides precise quantitative analysis of the abundance of total protein and post-
translationally modified protein analytes across multiple biological samples, including 
preclinical and clinical samples [14, 20, 21]. In contrast to standard ELISA based formats, in 
8 
 
“reverse phase” protein arrays, the protein analytes as part of crude tissue or whole cell 
lysate are immobilized on the solid phase and subsequently probed with antibodies toward 
a specific protein or modified protein epitope. The recent evolution of RPPA combined with 
robust sample preparation, more sophisticated sample handling, optical detection and 
better quality affinity reagents provides exquisite sensitivity (down to marker detection 
from single cell equivalents) and high sample throughput (100s of samples in parallel in one 
assay) at a reasonable cost per sample. This facilitates large-scale multiplex analysis of 
multiple post-translational markers across samples from in vitro, preclinical, or clinical 
samples. Recent applications include: Biomarker discovery in preclinical and clinical sample 
cohorts to identify post-translational prognostic or predictive biomarkers which correlate 
with disease progression or therapeutic response [22, 23]; Profiling drug MOA by pathway 
network analysis across dose-response and time-series studies in biological samples 
following compound exposure and correlation with phenotypic effects to determine 
pharmacodynamic biomarkers and novel pathway interaction networks. [14, 24]. Profiling 
pathway network response in biological samples before and after compound exposure to 
determine the activation state of druggable pathways which correlate with drug insensitivity 
or drug resistance and which can be mapped to drug-target databases thus informing upon 
rational drug combination strategies[25, 26]. 
RPPA employs the following core processes: total protein extracts are prepared from cell 
culture (2D/3D), animal (e.g. Xenograft models) or human clinical tissue using quality 
assured procedures, and samples are spotted onto nitrocellulose or a hydrophobic-coated 
chip surface, in a miniaturized dot-blot manner, using automated sample printing systems. 
The extracted protein sample sets are printed across multiple distinct locations (sub-arrays) 
physically separated from each other. Immobilized protein sub-arrays are then incubated 
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with distinct mono-specific antibodies to detect individual proteins, or their post-
translationally modified forms in each (one antibody on one individual sub-array). Protein 
samples are typically printed as a concentration series in replicates and multiple exposure 
and/or curve fitting parameters ensure measurement of protein abundance is conducted in 
the linear range to obtain a single value (e.g. in RFI = Relative Fluorescence Intensity units) 
which provides an absolute or relative measure of protein abundance across a sample set 
(Figure 2). Because the primary antibodies are physically separated from each other 
between sub-arrays there is no issue of cross-reactivity between antibody reagents enabling 
unlimited multiplexing of RPPA validated antibodies. The majority of RPPA platforms require 
nano-litres of protein lysate and picogram-to-femtogram quantities of protein, so permitting 
analysis of small preclinical and clinical samples for up to 100s of proteins of interest. The 
Zeptosens platform uses planar waveguide technology encompassing nano-structured glass 
protein array chips, further enhancing the read-out sensitivity (Figure 2) [20]. Excitation 
laser light is directed into the waveguiding layer by means of a nano-structured diffractive 
grating on the chip surface, orthogonally to the fluorescence emission path. The evanescent 
measurement of bound, labelled antibodies by the ZeptoREADER is confined to the sample 
surface, minimizing background interference from unbound antibodies or excitation light, 
and maximizing signal-to-noise ratios regardless of the low levels of individual proteins [20]. 
In combination with well validated antibodies and a user-friendly, easy-to-handle assay 
equipment,  the Zeptosens platform provides exquisite sensitivity (zeptomole and single cell 
equivalent levels of protein abundance per spot), quantitative linear signal response and 
good assay robustness and reproducibility with CVs of approximately 4% in a direct low 
volume immunoassay that does not require further signal amplification steps [14, 20, 27]. 
The enhanced sensitivity provided by the advances in optical detection and protein 
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microarray design enables further miniaturization of sample detection (down to 400 pico-
litres) and accordingly lower sample and reagent volumes (Figure 2). Thus, while RPPA offers 
similar levels of reproducibility to ELISA and automated western blotting assay methods, 
RPPA can provide increased sensitivity of several orders of magnitude for low abundant 
proteins relative to ELISA, Western and Mass Spectrometry across hundreds of proteins and 
hundred of samples simultaneously [14]. 
 
The modern generation of RPPA platforms provides a cost-effective solution for high 
throughput post-translational pathway analysis and biomarker research, supporting a 
variety of clinical and preclinical applications.  An expanding set of validated mono-specific 
antibodies ensure RPPA methods can be used to profile broad pathway responses 
simultaneously. Pathways typically covered in RPPA studies include well-characterized 
canonical signalling pathways, multiple DNA repair, cell-cycle, growth and apoptosis-
regulating proteins, transcription factors and multiple histone modifications. The technical 
advances in RPPA detection methodologies are complemented by developments in standard 
operating procedures, reagents, liquid handling equipment and best-practices for, 
preservation of proteins and post-translational modifications, reproducible sample printing 
and analysis, tailored to the needs of complex mixtures of cell- or tissue-derived protein 
extracts [14]. Environmentally controlled liquid handling instruments that create highly 
uniform arrays of complex protein samples have significantly advanced the throughput, 
sensitivity and reproducibility of protein/antibody array based proteomics (Figure 2).  
 
RPPA profiling drug mechanism-of-action 
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An important area of modern drug discovery is the identification of predictive and 
pharmacodynamic biomarkers that direct dosing, patient stratification and/or inform on 
appropriate drug combination strategies to enhance efficacy and counteract anticipated 
drug resistance mechanisms. Separate studies by Cardnell et al and Ummanni et al. 
correlated drug sensitivity across a panel of cancer cell lines with basal levels of protein and 
post-translational modifications determined via RPPA to identify minimal sets of protein 
markers that predict drug sensitivity and resistance [25, 28]. Thus, RPPA can be used to 
identify therapeutic response markers that might be readily suitable for the development of 
antibody-based diagnostic tests to select patients for treatment studies. RPPA has also been 
used to uncover unanticipated MOA of drugs already in clinical use. Retrospective analysis 
of esophageal adenocarcinoma patients who were also being treated with the biguanide 
small molecule Metformin for diabetes demonstrated a better response to chemoradiation 
therapy compared with patients who were not receiving Metformin [29]. However, the 
MOA of Metformin in esophageal cancer was unknown. RPPA analysis applied to esophageal 
cancer cells treated with Metformin revealed inhibition of PI3K/mTOR signaling pathway, 
which correlated with reduced cell growth and increased apoptosis [30]. Using a similar 
approach, retrospective analysis comparing recurrence rates for breast cancer 
demonstrated a significant reduction in recurrence rates in breast cancer patients that were 
users of the lipid-lowering drug Simvastatin [31]. RPPA analysis of triple-negative breast 
cancer cell lines following Simvastatin treatment demonstrated decreased phosphorylation 
of FOXO3a. Subsequent knockdown of FOXO3a attenuated the effect of Simvastatin on 
suppression of 3D in vitro mammosphere formation and migration [32]. Corilagin, which has 
recently been identified as a major active component in a well-known herbal medicine 
(Phyllanthus niruri L.) elcits antitumor activity although an unknown mechanism. RPPA 
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analysis of a panel of ovarian cancer cell lines treated with Corilagin demonstrated 
suppression of canonical Smad and noncanonical ERK/AKT pathways, which correlated with 
inhibition of TGF-β secretion and TGF-β pathway activation [33].  
Another study combined RPPA analysis and whole genome RNA sequencing over a time 
series following compound exposure to evaluate the MOA of novel potent organometallic 
compounds in ovarian cancer cell lines [34]. RPPA analysis revealed that the organometallic 
compound induced a DNA damage signaling response with upregulation of p21, p53 and 
ATM proteins detected by RPPA [34]. Investigation into the signaling pathways mediated 
downstream of the therapeutic target FLT1 included RPPA analysis of bone marrow derived 
macrophages following exposure to the FLT1-neutralizing antibody MF1 [35]. These studies 
indicated that Focal Adhesion Kinase (FAK) signaling may represent the mechanistic link 
between FLT1 activation to downstream gene expression and thus represents an 
appropriate pharmacodynamic biomarker for FLT-1 targeting therapies [35]. Evaluation of a 
collection of small molecule Raf inhibitors, tested across a panel of patient derived 
melanoma cell lines which exhibit resistance to the approved BRAF inhibitor Vemurafenib 
identified two novel pan-Raf inhibitors, CCT196969 and CCT241161 which inhibited the 
growth of the Vemurafenib resistant melanoma lines [36]. RPPA analysis revealed that 
inhibition of the phosphorylation of Src by CCT196969 and CCT241161 correlated with 
sensitivity in Vemurafenib resistant cell lines demonstrating that concurrent inhibition of Raf 
and Src family kinases co-operate to inhibit the growth of cells that are resistant to BRAF-
selective inhibitors [36]. RPPA analysis following treatment of a panel of AML (Acute 
Myeloid Leukaemia) cell lines with the small molecule pan-Pim kinase inhibitor AZD1208 
detected suppression of phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 
(Ser235/236), and 4E-BP1 (Ser65) consistent with a reduction in protein synthesis which 
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correlated with cell size reduction and growth inhibition following AZD1208 treatment [37]. 
Thus RPPA analysis reveals that mTOR pathway inhibition contributes to the MOA of 
AZD1208 [37]. While the majority of exemplar studies describing RPPA applications in drug 
MOA analysis have been applied to late-stage or approved drugs many of which have come 
from target-directed drug discovery, the success of this approach in revealing unanticipated 
drug MOA indicates this will also be a useful method for uncovering the MOA of hits and 
lead compounds derived from phenotypic screens. Phenotypic screening with non-
ribosomal peptide synthase (NRPS)-derived natural products has potential to provide a 
wealth of therapeutic leads, which explore broad areas of novel target biology owing to the 
extensive chemical and structural diversity that they encompass. Evaluation of the linear 
peptide bisebromoamide (BBA), isolated from a marine cyanobacterium in HCT116 
colorectal carcinoma cells demonstrated anti-growth and modulation of the actin 
cytoskeleton phenotypes [38]. Subsequent RPPA analysis of HCT116 pathway responses 
suggests BBA has a selective MOA with dose-dependent activity upon inhibition of protein 
levels of the oncogenic signaling protein, insulin receptor substrate (IRS-1) [38]. 
RPPA has also been used to identify new, unexpected mechanisms of targeted therapy 
resistance and compensatory signalling pathways. In such work the ability to quantitatively 
measure the activation state of many dozens of signalling proteins simultaneously over time 
identifies new PD biomarker and drug combination strategies which monitor and target 
adaptive resistance mechanisms [26]. The identification of feedback loop mechanism 
pathway markers of drug resistance can be directly cross-referenced to approved drug or 
broader drug-target databases to build rational drug combination hypotheses for further 
testing [39]. While recent advances in RPPA technology have improved the sensitivity and 
fidelity of proteomic analysis across complex biological samples a number of limitations 
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remain. For example RPPA is dependent upon the availability and validation of high-quality 
monospecific antibody reagents that can detect with high affinity and specificity a protein or 
post-translationally modified protein on a solid matrix. The challenges associated with 
identifying and validating suitable antibody reagents limits most RPPA studies to analysis of 
a few hundred protein analytes, thus RPPA proteomic analysis is inherently biased to the 
pathways for which suitable antibody reagents are available. RPPA represents a 
homogeneous assay on complex cell lysates and thus does not provide sufficient spatial 
information of protein expression across cell subpopulations from heterogeneous samples 
such a co-culture assays or tissue samples. RPPA methods are currently not standardized 
between laboratories due to the broad variety of platforms, protein sample preparation 
protocols and analysis approaches. Despite these limitations the RPPA advances described 
in this article are poised to complement alternative genomic and mass spectrometry 
technologies by enabling rapid and cost-effective profiling of post-translational pathway 
network dynamics following compound exposure in biological systems.  
 
RPPA profiling for drug mechanism-of-action in 3D vs 2D model systems 
New advances in in vitro cell culture assay formats provide a variety of 3D-cell cultures 
systems which attempt to better mimic the extracellular composition and architecture of in 
vivo tissues. 3D in vitro models which utilize both natural and synthetic biomaterials are 
available in multiwell formats which have been developed specifically for medium- to high-
throughput phenotypic screening [40]. Specific focus and substantial research efforts have 
been placed on the development and application of 3D tumor spheroid assay systems which 
simulate the multicellular, 3D architecture and hypoxic characteristics of the in vivo tumor 
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microenvironment [41, 42]. 3D tumor spheroid models are readily amenable to RPPA 
profiling of drug and compound mechanism-of action at the molecular pathway level within 
such 3D microenvironments. As an example, Figure 3 shows that RPPA could successfully 
elucidate distinct molecular pathway response upon treatment with Torin 2 (shown here), 
one out of a number of compounds, studied in more detail from a phenotypic compound 
library screen: heterotypic 3D microtumors (3D HEY/NIH3T3 cell cultures, 500 µm diameter, 
kindly provided by Jens M. Kelm, InSphero AG, Schlieren, Switzerland) were  treated at IC50 
concentration at two different time points (1 h and 48 h) and subsequently analyzed with 
RPPA and almost 50 antibodies covering key nodes of different pathways. Log2 fold changes 
(ratios of treatment to vehicle control signals, in triplicate) revealed a clear inhibition of the 
PI3K/Akt/mTOR (Figure 3), with prominent down-regulation of downstream S6 ribosomal 
protein phosphorylated at Ser240/244, Ser235/236, and to a minor extent also for other 
markers, indicating a strong inhibitory effect on translation and cell growth control; no 
inhibition or cross-compensatory effects could be observed in the other pathways studied. 
 
Ex vivo culture of 3D human tissues or established cell lines seeded on human ex vivo tissue 
scaffolds potentially provide a more physiologically relevant tissue substrate albeit within a 
non-physiological environment with limited throughput for screening. One such example is 
represented in Figure 4 which represents an ex vivo culture of a green fluorescent protein 
(GFP) labelled human pancreatic cancer cell line (PANC-1) on a human 3D retroperitoneal 
tissue slice culture. Human abdominal peritoneal and retroperitoneal (behind the 
peritoneum) tissue is readily available from routine abdominal surgery and are composed of 
layers of epithelial mesothelium and connective tissue. The retroperitoneal tissue 
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represents a major site of pancreatic cancer metastasis [43]. Fresh retroperitoneal tissue 
available from human surgery was dissected by tissue slice and placed in the upper chamber 
of a transwell insert to form a 3D tissue substrate for in vitro cell culture (Figure 4). Protein 
extracts for RPPA analysis were prepared from the pancreatic cancer cell line, PANC-1 
cultured on a standard 2D cell culture plastic substrate and the 3D retroperitoneal tissue 
following 24hrs treatment with a 3-point log-dose response of Gemcitibine (1, 0.1 and 
0.01M) and DMSO control. Each treatment was performed in duplicate across all samples 
and protein extracts prepared from each sample were spotted onto the Zeptosens RPPA 
microarray chip at 4 separate dilutions (0.2; 0.15; 0.1 and 0.75mg/ml). A single relative 
fluorescence intensity (RFI) value relating to protein abundance is obtained for each 
pathway analyte by a weighted linear least squares fit through each dilution series and a 
standard deviation value is calculated from the fit and Sahpiro-Wilk statistical test of 
intensity distributions across all 8 data-points/replicate spots for each treatment.  RPPA 
analysis of the pathway signalling response of PANC-1 cells following exposure to the 
nucleoside analogue, Gemcitibine clearly shows a suppressed induction of the p53 DNA 
damage response and enhanced signalling through the SRC/FAK pathway in PANC-1 cells 
cultured on 3D retroperitoneal ex vivo tissue relative to 2D cell culture plastic substrates 
(Figure 4). This data demonstrates that the tissue microenvironment of retroperitoneal 
tissue can alter the intracellular signalling response of pancreatic cancer cells to 
Gemcitabine, including induction of cell growth and survival signalling and reduced 
activation of the p53 tumour suppressor pathway, which may contribute to drug resistance.  
In contrast to potent cell killing activity observed in standard 2D in vitro pancreatic cancer 
cell viability assays, drug resistance and poor efficacy response to Gemcitabine was 
observed in vivo and in clinical studies [44] [45]. These experiments were performed on 
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retroperitoneal tissue taken from a single patient, further studies are underway to 
determine the reproducibility or heterogeneity in pancreatic cancer cell response when 
cultured on genetically- and physiologically-distinct retroperitoneal tissue samples from 
different patients. Thus characterizing MOA in more disease relevant, heterogeneous, 3D ex 
vivo assays will help triage the most promising lead molecules or drug candidates and 
biomarkers to inform further investments in preclinical development or target 
deconvolution. 
 
Conclusions 
Advances in high-throughput genomic and proteomic technologies such as RPPA supports 
informed mechanistic classification and triaging of phenotypic hits to further assist target 
deconvolution and preclinical development. Such RPPA profiling of post-translational 
pathways can facilitate the selection of the most appropriate phenotypic hits to take 
forward into further preclinical development, identify new predictive and pharmacodynamic 
biomarkers or new assay endpoints to support further hit-to-lead chemical optimization, 
provide corroborative evidence for target deconvolution studies and support further 
preclinical development and translation towards clinical studies with or without conclusive 
target identification. This more in-depth biological investigation of drug MOA at pathway 
levels in complex 3D and ex vivo models are well placed to shift the PDD bottleneck from 
target deconvolution towards increased disease relevance and hopefully improved efficacy 
and drug discovery productivity. 
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Figure Legends 
Figure 1.  Phenotypic Drug Discovery Operating Model. Our proposal for more informative 
and productive phenotypic drug discovery includes the progression of phenotypic hits or 
lead compound identified from phenotypic screening assays through increasingly more 
complex and disease relevant preclinical models to build increased confidence in their 
translational potential and a deeper understanding for drug mechanism-of-action at the 
transcriptomic and post-transational pathway network levels to supper subsequent target 
deconvolution and/or further preclinical and clinical development with our without a single 
molecular target hypothesis. 
Figure 2. Reverse Phase Protein Array (RPPA) Procedure – Schematic describing the major 
steps in the RPPA experimental and analysis procedure. 
Figure 3. (A.) An example of the application of RPPA profiling of hit compounds identified 
from a 3Dtumour spheroid phenotypic assay. (B.) Elucidation of compound mechanism-of-
action (shown here for Torin 2) with heterotypic 3D microtumours (treated HEY/NIH3T3 
cultures, kindly prepared and provided by InSphero AG), tested with RPPA across 
PI3K/Akt/mTOR pathway and others (not shown). FC = fold change of treatment-to-control 
signals, N=3 replicates. Data show prominent down-regulation of S6 ribosomal protein 
phosphorylated at Ser240/244 and Ser235/236, indicating strong inhibition on translation 
and cell growth. 
Figure 4.  RPPA applied to 3D ex vivo tissue culture assays. The human pancreatic cancer cell 
line PANC-1 expressing green fluorescent protein (GFP) was cultured on standard 2D tissue 
culture plastic substrates (A.) or 3D human retroperitoneal (RP) ex vivo tissue obtained from 
general surgery (B.). Exposure of PANC-1 cells cultured in 2D cell culture to Gemcitibine 
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induced a clear induction in total and phosphorylated p53 levels (C.) and a modest induction 
of p38MAPK protein levels (D.).  Culture of PANC-1 cells on 3D retroperitoneal (RP) ex-vivo 
tissue results in a dramatic reduction in Gemcitibine stimulation of p53 tumour suppressor 
and p38MAPK stress protein response (C. and D.).  Culture of PANC-1 cells on 3D 
retroperitoneal (RP) ex-vivo tissue also promoted increased stimulation of Focal Adhesion 
Kinase (FAK) (E.) and Src kinase (F.) signalling in response to Gemcitibine exposure relative 
to PANC-1 cells cultured on 2D plastic. All RPPA values represent abundance of protein 
analytes normalized to DMSO control treatments for each culture substrate (2D and 3D 
retroperitoneal tissue) with standard deviation values across samples replicates. 
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